€58.4m market cap

€0.75 last close

Onxeo’s lead compound, AsiDNA, is a first-in-class DNA break repair inhibitor based on a unique decoy mechanism. Currently it is in a Phase Ib trial with preliminary results expected by end 2020. AsiDNA has a broad potential and can be combined with various anticancer treatments.

Investment summary

Onxeo’s portfolio focuses on its novel platON platform, from which AsiDNA was the first product to enter clinical development. AsiDNA is the only oligonucleotide decoy agonist in development that disrupts and exhausts the tumour DNA damage response mechanism. To date, the only approved similar class of drugs are four commercially successful PARP inhibitors. AsiDNA is now being tested in the Phase Ib part of the DRIIV-1 trial at the Institut Curie in Paris in patients with advanced solid tumours in combination with chemotherapy. Another key Phase Ib/II trial, REVOCAN, should start soon and will evaluate AsiDNA’s potentially unique ability to reverse tumour resistance to the PARP inhibitor, niraparib. The outcomes of all these events will define AsiDNA’s mid- to late-stage development.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2018A 6.1 (3.4) (4.2) 0.05 1490.0 N/A
2019A 4.3 (9.1) (11.5) (0.15) N/A N/A
2020E 9.6 (4.1) (4.8) (0.07) N/A N/A
2021E 3.5 (10.5) (11.1) (0.17) N/A N/A
Industry outlook

Approval of the first PARP inhibitors has kick-started interest by the scientific community and large pharma in the DNA Damage Response field. Few biotechs are already positioned in this emerging field that has broad potential.

Last updated on 02/07/2020
Share price graph
Balance sheet
Forecast net cash (€m) 2.1
Forecast gearing ratio (%) N/A
Price performance
Actual (5.2) 69.3 (5.7)
Relative* (8.3) 41.4 4.3
52-week high/low €0.8/€0.3
*% relative to local index
Key management
Judith Greciet CEO
Nicolas Fellmann CFO
Valérie Leroy Director, Investor Relations & Corporate Com